Table 4.
Diagnostic value of miRNAs in HBV-related HCC.
| miRNA | Sample details | Diagnostic value | References | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Sample type | Size of case | Underlying cirrhosis, % | Control | Specificity (%) | Sensitivity (%) | AUC | CI of AUC | ||
| miR-18a | S | 101 HBV-HCC | NA | 60 HC | 75.0 | 86.1 | 0.881 | 0.829–0.933 | (44) |
| 101 HBV-HCC | NA | 30 CHB or LC | 70.0 | 77.2 | 0.775 | 0.681–0.869 | (44) | ||
| miR-21 | S | 101 HCC (76 HBV) | NA | 89 HC | 73.5 | 84 | 0.87 | 0.81–0.93 | (42) |
| 57 HBV-HCC | NA | 30 HC + 29 HBV | 71.2 | 89.5 | 0.865 | NA | (116) | ||
| miR-101 | S | 67 HBV-HCC | NA | 30 HC | 70.0 | 76.1 | 0.788 | 0.693–0.865 | (29) |
| 67 HBV-HCC | NA | 79 CHB | 62.0 | 88.1 | 0.777 | 0.701–0.842 | (29) | ||
| 67 HBV-HCC | NA | 61 HBV-LC | 90.2 | 95.5 | 0.976 | 0.931–0.995 | (29) | ||
| miR-122 | S | 70 HBV-HCC | 75% (51/68) | 34 HC | 83.3 | 81.6 | 0.869 | 0.786–0.952 | (43) |
| 70 HBV-HCC | 75% (51/68) | 48 CHB | 57.8 | 77.6 | 0.63 | 0.516–0.743 | (43) | ||
| 101 HCC (76 HBV) | NA | 89 HC | 69.1 | 70.7 | 0.79 | 0.71–0.86 | (42) | ||
| miR-139 | P | 31 HBV-HCC | NA | 31 CHB | 58.1 | 80.6 | 0.761 | 0.643–0.878 | (22) |
| miR-223 | S | 101 HCC (76 HBV) | NA | 89 HC | 80 | 76.5 | 0.86 | 0.80–0.92 | (42) |
| miR-15b and miR-130b | S | 57 HBV-HCC | NA | 30 HC + 29 HBV | 91.5 | 98.3 | 0.981 | NA | (116) |
| miR-27b-3p, miR-192-5p | S | 212 HBV-HCC | NA | 110 HC + 106 HBV- LC | 91.2 | 68.6 | 0.836 | 0.783–0.880 | (48) |
| 110 HC | 95.2 | 68.5 | 0.823 | 0.748–0.866 | |||||
| 106 HBV-LC | 79.3 | 78.5 | 0.859 | 0.804–0.906 | |||||
| miR-29a, miR-29c, miR-133a, miR-143, miR-145, miR-192, miR-505 | S | 153 HBV-HCC | NA | 60 HC + 68 CHB + 71 HBV-LC | 88.9 | 74.5 | 0.817 | 0.769–0.865 | (117) |
| 153 HBV-HCC | NA | 68 CHB + 71 HBV-LC | 89.9 | 74.5 | 0.822 | 0.772–0.873 | |||
| 49 HBV-HCC | NA | 48 HC + 42 inactive HBsAg carrier + | 91.1 | 85.7 | 0.884 | 0.818–0.951 | |||
| 49 HBV-HCC | NA | 42 inactive HBsAg carrier | 83.3 | 85.7 | 0.845 | 0.758–0.932 | |||
| 27 HBV-HCC | NA | 135 matched CHB | 80.0 | 70.4 | 0.752 | 0.644–0.860 | |||
| miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, miR-801 | P | 457 HBV-HCC | NA | 141 HBV-LC + 169 CHB + 167 HC | 83.5 | 81.8 | 0.888 | 0.852–0.917 | (45) |
| 167 HC | 93.9 | 83.2 | 0.941 | 0/905–0.966 | |||||
| 169 CHB | 76.4 | 79.1 | 0.842 | 0.792–0.883 | |||||
| 141 HBV-LC | 91.1 | 75 | 0.884 | 0.838–0.921 | |||||
| miR122, miR1228, miR141, miR192, miR199a, miR206, miR26a, miR433 | S | 261 HBV-HCC | NA | 173 HC + 233 HBV-LC | 76.2 | 90.3 | 0.879 | 0.842–0.941 | (46) |
| 173 HC | 83.3 | 82.8 | 0.893 | 0.849–0.94 | |||||
| 233 HBV-LC | 84.6 | 81.6 | 0.892 | 0.844–0.939 | |||||
| miR-20a-5p, miR-25-3p, miR-30a-5p, miR-92a-3p, miR-132-3p, miR-185-5p, miR-320a, miR-324-3p | P | 67 HBV-HCC | NA | 82 HBV | 64.6 | 86.6 | 0.802 | NA | (118) |
When data from training set and validation set are available, only the latter is presented. AUC, area under the curve; CHB, chronic hepatitis B; CI, confidence interval; HBV, Hepatitis B virus; HC, healthy control; HCC, hepatocellular carcinoma; LC, liver cirrhosis; NA, not available; P, plasma; S, serum.